Biotech Showcase™ 2017: AmpliPhi advances phage in clinic to address microbial infections

January 23, 2017
Using cocktails of bacteriophages to attack bacterial infections, San Diego-based AmpliPhi announced progress in Phase I studies of its lead program. Company CEO Scott Salka explains to Mike Ward, Informa Pharma Intelligence’s insights global director of content, how he is looking to secure sufficient capital to support the Phase II development of its lead program against chronic rhinosinusitis while advancing other candidate products.
Previous Video
Biotech Showcase™ 2017: Q BioMed plans to accelerate up to four more assets
Biotech Showcase™ 2017: Q BioMed plans to accelerate up to four more assets

Established in June 2015, Q BioMed, the NYC-based biomedical acceleration development company, is looking t...

Next Video
Biotech Showcase™ 2017: Refocusing Tarveda on tumor-targeted mini-drug conjugates
Biotech Showcase™ 2017: Refocusing Tarveda on tumor-targeted mini-drug conjugates

In the past 18 months, Tarveda Therapeutics has been refocusing its efforts on Pentarins, its miniaturized ...